1-18 of 18
Scott J. Rodig
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Next-Generation Sequencing–Based MSI Scoring Predicts Benefit in Mismatch Repair–Deficient Tumors Treated with Nivolumab: Follow-up on NCI-MATCH Arm Z1D

Open Access
Jonathan D. Schoenfeld, Nilofer S. Azad, Jacob Gross, Li Chen, Michael J. Overman, Katrina Kao, Latifa Jackson, Donna Brunnquell, Xiangning Bu, Christina Coppola, Ping Guan, Jennifer Lee, David Sims, Rebecca Fuchs, Jason L. Weirather, Kathleen L. Pfaff, Lauren Gunasti, Srin Ranasinghe, Stanley R. Hamilton, Victoria Wang, Peter J. O’Dwyer, Catherine J. Wu, Scott J. Rodig, David R. Patton, Lyndsay Harris
Journal: Clinical Cancer Research
Clin Cancer Res (2025) 31 (4): 667–677.
https://doi.org/10.1158/1078-0432.CCR-24-0427
Published: 17 February 2025
View articletitled, Next-Generation Sequencing–Based MSI Scoring Predicts Benefit in Mismatch Repair–Deficient Tumors Treated with Nivolumab: Follow-up on NCI-MATCH Arm Z1D
Open the PDF for Next-Generation Sequencing–Based MSI Scoring Predicts Benefit in Mismatch Repair–Deficient Tumors Treated with Nivolumab: Follow-up on NCI-MATCH Arm Z1D in another window
Includes: Supplementary data
Journal Articles

Correction: A Randomized Trial of Combined PD-L1 and CTLA-4 Inhibition with Targeted Low-dose or Hypofractionated Radiation for Patients with Metastatic Colorectal Cancer

Free
Arta M. Monjazeb, Anita Giobbie-Hurder, Ana Lako, Emily M. Thrash, Ryan C. Brennick, Katrina Z. Kao, Claire Manuszak, Ryan D. Gentzler, Anteneh Tesfaye, Salma K. Jabbour, Olatunji B. Alese, Osama E. Rahma, James M. Cleary, Elad Sharon, Harvey J. Mamon, May Cho, Howard Streicher, Helen X. Chen, Mansoor M. Ahmed, Adrian Mariño-Enríquez, Seunghee Kim-Schulze, Sacha Gnjatic, Emanual Maverakis, Alina I. Marusina, Alexander A. Merleev, Mariano Severgnini, Kathleen L. Pfaff, James Lindsay, Jason L. Weirather, Srinika Ranasinghe, Alexander Spektor, Scott J. Rodig, F. Stephen Hodi, Jonathan D. Schoenfeld
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (17): 4940.
https://doi.org/10.1158/1078-0432.CCR-21-2698
Published: 01 September 2021
View articletitled, Correction: A Randomized Trial of Combined PD-L1 and CTLA-4 Inhibition with Targeted Low-dose or Hypofractionated Radiation for Patients with Metastatic Colorectal Cancer
Open the PDF for Correction: A Randomized Trial of Combined PD-L1 and CTLA-4 Inhibition with Targeted Low-dose or Hypofractionated Radiation for Patients with Metastatic Colorectal Cancer in another window
Journal Articles

A Randomized Trial of Combined PD-L1 and CTLA-4 Inhibition with Targeted Low-Dose or Hypofractionated Radiation for Patients with Metastatic Colorectal Cancer

Available to Purchase
Arta M. Monjazeb, Anita Giobbie-Hurder, Ana Lako, Emily M. Thrash, Ryan C. Brennick, Katrina Z. Kao, Claire Manuszak, Ryan D. Gentzler, Anteneh Tesfaye, Salma K. Jabbour, Olatunji B. Alese, Osama E. Rahma, James M. Cleary, Elad Sharon, Harvey J. Mamon, May Cho, Howard Streicher, Helen X. Chen, Mansoor M. Ahmed, Adrian Mariño-Enríquez, Seunghee Kim-Schulze, Sacha Gnjatic, Emanual Maverakis, Alina I. Marusina, Alexander A. Merleev, Mariano Severgnini, Kathleen L. Pfaff, James Lindsay, Jason L. Weirather, Srinika Ranasinghe, Alexander Spektor, Scott J. Rodig, F. Stephen Hodi, Jonathan D. Schoenfeld
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (9): 2470–2480.
https://doi.org/10.1158/1078-0432.CCR-20-4632
Published: 01 May 2021
View articletitled, A Randomized Trial of Combined PD-L1 and CTLA-4 Inhibition with Targeted Low-Dose or Hypofractionated Radiation for Patients with Metastatic Colorectal Cancer
Open the PDF for A Randomized Trial of Combined PD-L1 and CTLA-4 Inhibition with Targeted Low-Dose or Hypofractionated Radiation for Patients with Metastatic Colorectal Cancer in another window
Includes: Supplementary data
Journal Articles

Correction: Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus–unrelated Head and Neck Cancer: A Multicenter, Phase II Trial

Free
Ravindra Uppaluri, Katie M. Campbell, Ann Marie Egloff, Paul Zolkind, Zachary L. Skidmore, Brian Nussenbaum, Randal C. Paniello, Jason T. Rich, Ryan Jackson, Patrik Pipkorn, Loren S. Michel, Jessica Ley, Peter Oppelt, Gavin P. Dunn, Erica K. Barnell, Nicholas C. Spies, Tianxiang Lin, Tiantian Li, David T. Mulder, Youstina Hanna, Iulia Cirlan, Trevor J. Pugh, Tenny Mudianto, Rachel Riley, Liye Zhou, Vickie Y. Jo, Matthew D. Stachler, Glenn J. Hanna, Jason Kass, Robert Haddad, Jonathan D. Schoenfeld, Evisa Gjini, Ana Lako, Wade Thorstad, Hiram A. Gay, Mackenzie Daly, Scott J. Rodig, Ian S. Hagemann, Dorina Kallogjeri, Jay F. Piccirillo, Rebecca D. Chernock, Malachi Griffith, Obi L. Griffith, Douglas R. Adkins
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (1): 357.
https://doi.org/10.1158/1078-0432.CCR-20-4484
Published: 04 January 2021
View articletitled, Correction: Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus–unrelated Head and Neck Cancer: A Multicenter, Phase II Trial
Open the PDF for Correction: Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus–unrelated Head and Neck Cancer: A Multicenter, Phase II Trial in another window
Journal Articles

Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus–Unrelated Head and Neck Cancer: A Multicenter, Phase II Trial

Available to Purchase
Ravindra Uppaluri, Katie M. Campbell, Ann Marie Egloff, Paul Zolkind, Zachary L. Skidmore, Brian Nussenbaum, Randal C. Paniello, Jason T. Rich, Ryan Jackson, Patrik Pipkorn, Loren S. Michel, Jessica Ley, Peter Oppelt, Gavin P. Dunn, Erica K. Barnell, Nicholas C. Spies, Tianxiang Lin, Tiantian Li, David T. Mulder, Youstina Hanna, Iulia Cirlan, Trevor J. Pugh, Tenny Mudianto, Rachel Riley, Liye Zhou, Vickie Y. Jo, Matthew D. Stachler, Glenn J. Hanna, Jason Kass, Robert Haddad, Jonathan D. Schoenfeld, Evisa Gjini, Ana Lako, Wade Thorstad, Hiram A. Gay, Mackenzie Daly, Scott J. Rodig, Ian S. Hagemann, Dorina Kallogjeri, Jay F. Piccirillo, Rebecca D. Chernock, Malachi Griffith, Obi L. Griffith, Douglas R. Adkins
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (19): 5140–5152.
https://doi.org/10.1158/1078-0432.CCR-20-1695
Published: 01 October 2020
View articletitled, Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus–Unrelated Head and Neck Cancer: A Multicenter, Phase II Trial
Open the PDF for Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus–Unrelated Head and Neck Cancer: A Multicenter, Phase II Trial in another window
Includes: Supplementary data
Journal Articles

Abstract A04: Profiling DNA damage repair and immunophenotypes in BRCA1/2 mutated high-grade serous ovarian cancers

Free
Anniina Farkkila, Bose Kochupurakkal, Brooke E. Howitt, Kyle C. Strickland, Dipanjan Chowdhury, Geoffrey Shapiro, Evisa Gjini, Scott J. Rodig, Ursula A. Matulonis, Panagiotis Konstantinopoulos, Alan D. D’Andrea
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (15_Supplement): A04.
https://doi.org/10.1158/1557-3265.OVCA17-A04
Published: 01 August 2018
View articletitled, Abstract A04: Profiling DNA damage repair and immunophenotypes in BRCA1/2 mutated high-grade serous ovarian cancers
Journal Articles

Abstract 17: In situ immune expression signatures before and after ipilimumab therapy for relapsed acute myeloid leukemia after allogeneic stem cell transplantation

Free
Pavan Bachireddy, Matthew S. Davids, Michael S. Rooney, Michaela Bowden, Chensheng W. Zhou, Scott J. Rodig, Vincent Ho, Joseph Antin, John Koreth, Edwin Alyea, Robert J. Soiffer, Catherine J. Wu
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (24_Supplement): 17.
https://doi.org/10.1158/1557-3265.HEMMAL17-17
Published: 14 December 2017
View articletitled, Abstract 17: In situ immune expression signatures before and after ipilimumab therapy for relapsed acute myeloid leukemia after allogeneic stem cell transplantation
Journal Articles

Immunohistochemical Loss of LKB1 Is a Biomarker for More Aggressive Biology in KRAS-Mutant Lung Adenocarcinoma

Available to Purchase
Antonio Calles, Lynette M. Sholl, Scott J. Rodig, Ashley K. Pelton, Jason L. Hornick, Mohit Butaney, Christine Lydon, Suzanne E. Dahlberg, Geoffrey R. Oxnard, David M. Jackman, Pasi A. Jänne
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (12): 2851–2860.
https://doi.org/10.1158/1078-0432.CCR-14-3112
Published: 14 June 2015
View articletitled, Immunohistochemical Loss of LKB1 Is a Biomarker for More Aggressive Biology in KRAS-Mutant Lung Adenocarcinoma
Open the PDF for Immunohistochemical Loss of LKB1 Is a Biomarker for More Aggressive Biology in KRAS-Mutant Lung Adenocarcinoma in another window
Includes: Supplementary data
Journal Articles

Selective JAK2 Inhibition Specifically Decreases Hodgkin Lymphoma and Mediastinal Large B-cell Lymphoma Growth In Vitro and In Vivo

Free
Yansheng Hao, Bjoern Chapuy, Stefano Monti, Heather H. Sun, Scott J. Rodig, Margaret A. Shipp
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2014) 20 (10): 2674–2683.
https://doi.org/10.1158/1078-0432.CCR-13-3007
Published: 14 May 2014
View articletitled, Selective JAK2 Inhibition Specifically Decreases Hodgkin Lymphoma and Mediastinal Large B-cell Lymphoma Growth In Vitro and In Vivo
Open the PDF for Selective JAK2 Inhibition Specifically Decreases Hodgkin Lymphoma and Mediastinal Large B-cell Lymphoma Growth In Vitro and In Vivo in another window
Includes: Supplementary data
Journal Articles

PD-L1 Expression Is Characteristic of a Subset of Aggressive B-cell Lymphomas and Virus-Associated Malignancies

Available to Purchase
Benjamin J. Chen, Bjoern Chapuy, Jing Ouyang, Heather H. Sun, Margaretha G.M. Roemer, Mina L. Xu, Hongbo Yu, Christopher D.M. Fletcher, Gordon J. Freeman, Margaret A. Shipp, Scott J. Rodig
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (13): 3462–3473.
https://doi.org/10.1158/1078-0432.CCR-13-0855
Published: 30 June 2013
View articletitled, PD-L1 Expression Is Characteristic of a Subset of Aggressive B-cell Lymphomas and Virus-Associated Malignancies
Open the PDF for PD-L1 Expression Is Characteristic of a Subset of Aggressive B-cell Lymphomas and Virus-Associated Malignancies in another window
Includes: Supplementary data
Journal Articles

Quantitative Immunofluorescence Reveals the Signature of Active B-cell Receptor Signaling in Diffuse Large B-cell Lymphoma

Available to Purchase
Agata M. Bogusz, Richard H.G. Baxter, Treeve Currie, Papiya Sinha, Aliyah R. Sohani, Jeffery L. Kutok, Scott J. Rodig
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (22): 6122–6135.
https://doi.org/10.1158/1078-0432.CCR-12-0397
Published: 14 November 2012
View articletitled, Quantitative Immunofluorescence Reveals the Signature of Active B-cell Receptor Signaling in Diffuse Large B-cell Lymphoma
Open the PDF for Quantitative Immunofluorescence Reveals the Signature of Active B-cell Receptor Signaling in Diffuse Large B-cell Lymphoma in another window
Includes: Supplementary data
Journal Articles

Ganetespib (STA-9090), a Nongeldanamycin HSP90 Inhibitor, Has Potent Antitumor Activity in In Vitro and In Vivo Models of Non–Small Cell Lung Cancer

Available to Purchase
Takeshi Shimamura, Samanthi A. Perera, Kevin P. Foley, Jim Sang, Scott J. Rodig, Takayo Inoue, Liang Chen, Danan Li, Julian Carretero, Yu-Chen Li, Papiya Sinha, Christopher D. Carey, Christa L. Borgman, John-Paul Jimenez, Matthew Meyerson, Weiwen Ying, James Barsoum, Kwok-Kin Wong, Geoffrey I. Shapiro
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (18): 4973–4985.
https://doi.org/10.1158/1078-0432.CCR-11-2967
Published: 16 September 2012
View articletitled, Ganetespib (STA-9090), a Nongeldanamycin HSP90 Inhibitor, Has Potent Antitumor Activity in In Vitro and In Vivo Models of Non–Small Cell Lung Cancer
Open the PDF for Ganetespib (STA-9090), a Nongeldanamycin HSP90 Inhibitor, Has Potent Antitumor Activity in In Vitro and In Vivo Models of Non–Small Cell Lung Cancer in another window
Includes: Supplementary data
Journal Articles

Expression of Interleukin-4 Receptor Alpha in Human Pleural Mesothelioma Is Associated with Poor Survival and Promotion of Tumor Inflammation

Available to Purchase
Bryan M. Burt, Andrew Bader, Daniel Winter, Scott J. Rodig, Raphael Bueno, David J. Sugarbaker
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (6): 1568–1577.
https://doi.org/10.1158/1078-0432.CCR-11-1808
Published: 14 March 2012
View articletitled, Expression of Interleukin-4 Receptor Alpha in Human Pleural Mesothelioma Is Associated with Poor Survival and Promotion of Tumor Inflammation
Open the PDF for Expression of Interleukin-4 Receptor Alpha in Human Pleural Mesothelioma Is Associated with Poor Survival and Promotion of Tumor Inflammation in another window
Includes: Supplementary data
Journal Articles

MLL-Rearranged B Lymphoblastic Leukemias Selectively Express the Immunoregulatory Carbohydrate-Binding Protein Galectin-1

Available to Purchase
Przemyslaw Juszczynski, Scott J. Rodig, Jing Ouyang, Evan O'Donnell, Kunihiko Takeyama, Wojciech Mlynarski, Katarzyna Mycko, Tomasz Szczepanski, Anna Gaworczyk, Andrei Krivtsov, Joerg Faber, Amit U. Sinha, Gabriel A. Rabinovich, Scott A. Armstrong, Jeffery L. Kutok, Margaret A. Shipp
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (7): 2122–2130.
https://doi.org/10.1158/1078-0432.CCR-09-2765
Published: 31 March 2010
View articletitled, MLL-Rearranged B Lymphoblastic Leukemias Selectively Express the Immunoregulatory Carbohydrate-Binding Protein Galectin-1
Open the PDF for MLL-Rearranged B Lymphoblastic Leukemias Selectively Express the Immunoregulatory Carbohydrate-Binding Protein Galectin-1 in another window
Includes: Supplementary data
Journal Articles

A Novel, Highly Sensitive Antibody Allows for the Routine Detection of ALK-Rearranged Lung Adenocarcinomas by Standard Immunohistochemistry

Available to Purchase
Mari Mino-Kenudson, Lucian R. Chirieac, Kenny Law, Jason L. Hornick, Neal Lindeman, Eugene J. Mark, David W. Cohen, Bruce E. Johnson, Pasi A. Jänne, A. John Iafrate, Scott J. Rodig
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (5): 1561–1571.
https://doi.org/10.1158/1078-0432.CCR-09-2845
Published: 28 February 2010
View articletitled, A Novel, Highly Sensitive Antibody Allows for the Routine Detection of ALK-Rearranged Lung Adenocarcinomas by Standard Immunohistochemistry
Open the PDF for A Novel, Highly Sensitive Antibody Allows for the Routine Detection of ALK-Rearranged Lung Adenocarcinomas by Standard Immunohistochemistry in another window
Includes: Supplementary data
Journal Articles

Unique Clinicopathologic Features Characterize ALK-Rearranged Lung Adenocarcinoma in the Western Population

Available to Purchase
Scott J. Rodig, Mari Mino-Kenudson, Sanja Dacic, Beow Y. Yeap, Alice Shaw, Justine A. Barletta, Hannah Stubbs, Kenny Law, Neal Lindeman, Eugene Mark, Pasi A. Janne, Thomas Lynch, Bruce E. Johnson, A. John Iafrate, Lucian R. Chirieac
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (16): 5216–5223.
https://doi.org/10.1158/1078-0432.CCR-09-0802
Published: 12 August 2009
View articletitled, Unique Clinicopathologic Features Characterize ALK-Rearranged Lung Adenocarcinoma in the Western Population
Open the PDF for Unique Clinicopathologic Features Characterize ALK-Rearranged Lung Adenocarcinoma in the Western Population in another window
Includes: Supplementary data
Journal Articles

AP1-Dependent Galectin-1 Expression Delineates Classical Hodgkin and Anaplastic Large Cell Lymphomas from Other Lymphoid Malignancies with Shared Molecular Features

Available to Purchase
Scott J. Rodig, Jing Ouyang, Przemyslaw Juszczynski, Treeve Currie, Kenneth Law, Donna S. Neuberg, Gabriel A. Rabinovich, Margaret A. Shipp, Jeffery L. Kutok
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (11): 3338–3344.
https://doi.org/10.1158/1078-0432.CCR-07-4709
Published: 02 June 2008
View articletitled, AP1-Dependent Galectin-1 Expression Delineates Classical Hodgkin and Anaplastic Large Cell Lymphomas from Other Lymphoid Malignancies with Shared Molecular Features
Open the PDF for AP1-Dependent Galectin-1 Expression Delineates Classical Hodgkin and Anaplastic Large Cell Lymphomas from Other Lymphoid Malignancies with Shared Molecular Features in another window
Journal Articles

Heterogeneous CD52 Expression among Hematologic Neoplasms: Implications for the Use of Alemtuzumab (CAMPATH-1H)

Available to Purchase
Scott J. Rodig, Jeremy S. Abramson, Geraldine S. Pinkus, Steven P. Treon, David M. Dorfman, Henry Y. Dong, Margaret A. Shipp, Jeffery L. Kutok
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (23): 7174–7179.
https://doi.org/10.1158/1078-0432.CCR-06-1275
Published: 04 December 2006
View articletitled, Heterogeneous CD52 Expression among Hematologic Neoplasms: Implications for the Use of Alemtuzumab (CAMPATH-1H)
Open the PDF for Heterogeneous CD52 Expression among Hematologic Neoplasms: Implications for the Use of Alemtuzumab (CAMPATH-1H) in another window